09:40 AM EST - Oncolytics Biotech® Inc. : Announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment. Oncolytics Biotech® Inc.
shares T.ONC are trading unchanged at $0.56.
